Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.
Start | Author Index

642.O2.6 Chronic Lymphocytic Leukemia - Therapy, Excluding Transplantation

Sunday, December 7, 2008: 4:30 PM-6:00 PM
2005-2007-2018-2020 - West (Moscone Center)
Moderators:
Nicole Lamanna, MD and Claire E. Dearden, MD
4:30 PM
43
Cyclophosphamide Remains An Important Component of Treatment in CLL Patients Receiving Pentostatin and Rituximab Based ChemoimmunotherapyClinically Relevant Abstract

Neil E. Kay1, Wenting Wu2*, John C. Byrd, MD3, Brian Kabat2*, Diane F. Jelinek, PhD4, Clive S. Zent, MD5, Timothy Call2*, Thomas Lin, MD, PhD6 and Tait Shanafelt2*

1College of Medicine, Mayo Clinic, Rochester, MN
2Mayo Clinic, Rochester, MN
3The Ohio State University, Columbus, OH
4Mayo Clinic/Foundation, Rochester, MN
5Dept. of Hematology, Mayo Clinic, Rochester, MN
6Division of Hematology and Oncology, The Ohio State Univ., Columbus, OH
4:45 PM
44
A Phase II Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)

Christine Chen, MD1, Harminder Paul2*, Wei Xu, PhD3*, Vishal Kukreti2*, Suzanne Trudel2, Ellen Wei2*, Zhi Hua Li2*, Joseph Brandwein2*, Mariela Pantoja2* and Chungyee Leung-Hagensteijn2*

1Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada
2Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada
3Biostatistics, Princess Margaret Hospital, Toronto, ON, Canada
5:00 PM
45
Lenalidomide as Initial Treatment of Elderly Patients with Chronic Lymphocytic Leukemia (CLL)Clinically Relevant Abstract

Alessandra Ferrajoli1, Susan O'Brien1, William Wierda1, Stefan Faderl1*, Steven Kornblau2*, Kimberly Yerrow1*, Zeev Estrov1*, Hagop Kantarjian1* and Michael Keating1*

1Department of Leukemia, U.T.M.D. Anderson Cancer Center, Houston, TX
2Department of Stem Cell Transplantation, U.T.M.D. Anderson Cancer Center, Houston, TX
5:15 PM
46
Flavopiridol (Alvocidib) Induces Durable Responses in Relapsed Chronic Lymphocytic Leukemia (CLL) Patients with High-Risk Cytogenetic Abnormalities

Thomas S. Lin, MD, PhD, Nyla A. Heerema, PhD, Gerard Lozanski, MD*, Beth Fischer, BSN, RN*, Kristie A. Blum, MD, Leslie A. Andritsos, MD, Jeffrey A. Jones, MD, Joseph M. Flynn, DO, MPH*, Mollie E. Moran, MSN, CNP*, Sarah Mitchell*, Amy J. Johnson, PhD*, Mitch A. Phelps, PhD*, Michael R. Grever, MD and John C. Byrd, MD

The Ohio State University, Columbus, OH
5:30 PM
47
Rituximab and High-Dose Methylprednisolone for the Initial Treatment of Chronic Lymphocytic Leukemia Is Associated with Promising Clinical Activity and Minimal Hematologic Toxicity

Danelle F James, M.D.1*, Januario E. Castro, M.D.1*, Jose David Sandoval-Sus, M.D.1*, Sonia Jain, Ph.D.2*, Janet Bole, R.N.3*, Laura Rassenti, Ph.D.1 and Thomas J. Kipps, M.D., Ph.D.1

1Moores UCSD Cancer Center, CLL Research Consortium, La Jolla, CA
2Moores UCSD Cancer Center, CLL Research Consortium, Division of Biostatistics and Bioinformatics UCSD, La Jolla, CA
3.
5:45 PM
48
Changes in the Natural History, Treatment Modalities, and Survival Patterns in Patients with Chronic Lymphocytic Leukemia (CLL) from 1980 to 2008. The Hospital Clinic of Barcelona Experience

Pau Abrisqueta, MD1*, Francesc Bosch, MD, PhD1, Marta Aymerich, MD, PhD2*, Eva Gine, MD1*, Carol Moreno, MD, PhD1*, Maria Rozman, MD, PhD2*, Neus Villamor, MD, PhD2, Elias Campo, MD, PhD3*, Ciril Rozman, MD, PhD1* and Emili Montserrat, MD, PhD1

1Institute of Hematology and Oncology, dept. of Hematology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
2Hematopathology Unit, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
3Dept. of Pathology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain
See more of: Oral and Poster Abstracts
<< Previous Session | Next Session >>

*signifies non-member of ASH